Dual Role of Diallyl Disulfide (DADS) on Invasive Potential and β-Catenin Dynamics in HER2-Positive Breast Cancer Cells
Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Cells and Treatments
2.2. Apoptosis and Cell Cycle Analysis
2.3. Real-Time Cell Invasion Assays
2.4. Immunochemical Analysis
2.5. Immunocytochemical and Confocal Analysis
2.6. Survival Outcomes and β-Catenin Levels
2.7. Statistical Analysis
3. Results
3.1. Garlic Extract Reduces Cell Growth and Induces Invasive Potential in HER2-Overexpressing Breast Tumor Cells
3.2. Diallyl Disulfide Reduces Cell Growth and Induces Invasiveness in SKBR3 Breast Cancer Cells
3.3. The Effects of DADS on Invasive Potential of SKBR3 Cells Depend on the Duration of Treatment
3.4. DADS Modulates Akt and β-Catenin in Parallel with SKBR3 Invasion
3.5. Impacts on Patients’ Survival of β-Catenin Levels in Their HER2+ Tumors
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Xiong, X.; Zheng, L.W.; Ding, Y.; Chen, Y.F.; Cai, Y.W.; Wang, L.P.; Huang, L.; Liu, C.C.; Shao, Z.M.; Yu, K.D. Breast cancer: Pathogenesis and treatments. Signal Transduct. Target. Ther. 2025, 10, 49. [Google Scholar] [CrossRef] [PubMed]
- Tsang, J.Y.S.; Tse, G.M. Molecular Classification of Breast Cancer. Adv. Anat. Pathol. 2020, 27, 27–35. [Google Scholar] [CrossRef]
- Hayes, D.F. HER2 and Breast Cancer—A Phenomenal Success Story. N. Engl. J. Med. 2019, 381, 1284–1286. [Google Scholar] [CrossRef]
- Swain, S.M.; Shastry, M.; Hamilton, E. Targeting HER2-positive breast cancer: Advances and future directions. Nat. Rev. Drug Discov. 2023, 22, 101–126. [Google Scholar] [CrossRef]
- Mercogliano, M.F.; Bruni, S.; Mauro, F.L.; Schillaci, R. Emerging Targeted Therapies for HER2-Positive Breast Cancer. Cancers 2023, 15, 1987. [Google Scholar] [CrossRef]
- Molina, M.A.; Sáez, R.; Ramsey, E.E.; Garcia-Barchino, M.J.; Rojo, F.; Evans, A.J.; Albanell, J.; Keenan, E.J.; Lluch, A.; García-Conde, J.; et al. NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin. Cancer Res. 2002, 8, 347–353. [Google Scholar] [PubMed]
- Pedersen, K.; Angelini, P.D.; Laos, S.; Bach-Faig, A.; Cunningham, M.P.; Ferrer-Ramón, C.; Luque-García, A.; García-Castillo, J.; Parra-Palau, J.L.; Scaltriti, M.; et al. A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis. Mol. Cell. Biol. 2009, 29, 3319–3331. [Google Scholar] [CrossRef]
- Narayan, M.; Wilken, J.A.; Harris, L.N.; Baron, A.T.; Kimbler, K.D.; Maihle, N.J. Trastuzumab-induced HER reprogramming in “resistant” breast carcinoma cells. Cancer Res. 2009, 69, 2191–2194. [Google Scholar] [CrossRef] [PubMed]
- Sun, B.; Mason, S.; Wilson, R.C.; Hazard, S.E.; Wang, Y.; Fang, R.; Wang, Q.; Yeh, E.S.; Yang, M.; Roberts, T.M.; et al. Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers. Oncogene 2020, 39, 50–63. [Google Scholar] [CrossRef]
- Schlam, I.; Tarantino, P.; Tolaney, S.M. Overcoming Resistance to HER2-Directed Therapies in Breast Cancer. Cancers 2022, 14, 3996. [Google Scholar] [CrossRef]
- Ding, X.; Sharko, A.C.; McDermott, M.S.J.; Schools, G.P.; Chumanevich, A.; Ji, H.; Li, J.; Zhang, L.; Mack, Z.T.; Sikirzhytski, V.; et al. Inhibition of CDK8/19 Mediator kinase potentiates HER2-targeting drugs and bypasses resistance to these agents in vitro and in vivo. Proc. Natl. Acad. Sci. USA 2022, 119, e2201073119. [Google Scholar] [CrossRef] [PubMed]
- Marine, J.C.; Dawson, S.J.; Dawson, M.A. Non-genetic mechanisms of therapeutic resistance in cancer. Nat. Rev. Cancer 2020, 20, 743–756. [Google Scholar] [CrossRef]
- Filho, O.M.; Viale, G.; Stein, S.; Trippa, L.; Yardley, D.A.; Mayer, I.A.; Abramson, V.G.; Arteaga, C.L.; Spring, L.M.; Waks, A.G.; et al. Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab. Cancer Discov. 2021, 11, 2474–2487. [Google Scholar] [CrossRef]
- Berns, K.; Horlings, H.M.; Hennessy, B.T.; Madiredjo, M.; Hijmans, E.M.; Beelen, K.; Linn, S.C.; Gonzalez-Angulo, A.M.; Stemke-Hale, K.; Hauptmann, M.; et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12, 395–402. [Google Scholar] [CrossRef]
- Loibl, S.; Majewski, I.; Guarneri, V.; Nekljudova, V.; Holmes, E.; Bria, E.; Denkert, C.; Schem, C.; Sotiriou, C.; Loi, S.; et al. PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: Pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. Ann. Oncol. 2016, 27, 1519–1525. [Google Scholar] [CrossRef]
- Baselga, J.; Cortés, J.; Im, S.A.; Clark, E.; Ross, G.; Kiermaier, A.; Swain, S.M. Biomarker analyses in CLEOPATRA: A phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J. Clin. Oncol. 2014, 32, 3753–3761. [Google Scholar] [CrossRef]
- Baselga, J.; Lewis Phillips, G.D.; Verma, S.; Ro, J.; Huober, J.; Guardino, A.E.; Samant, M.K.; Olsen, S.; de Haas, S.L.; Pegram, M.D. Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer. Clin. Cancer Res. 2016, 22, 3755–3763. [Google Scholar] [CrossRef]
- Wang, Z.; Li, Z.; Ji, H. Direct targeting of β-catenin in the Wnt signaling pathway: Current progress and perspectives. Med. Res. Rev. 2021, 41, 2109–2129. [Google Scholar] [CrossRef] [PubMed]
- Hao, X.; Zheng, J.; Yu, X.; Li, Z.; Ren, G. β-catenin promotes resistance to trastuzumab in breast cancer cells through enhancing interaction between HER2 and SRC. Acta Biochim. Pol. 2023, 70, 261–269. [Google Scholar] [PubMed]
- Hsieh, T.H.; Hsu, C.Y.; Tsai, C.F.; Chiu, C.C.; Liang, S.S.; Wang, T.N.; Kuo, P.L.; Long, C.Y.; Tsai, E.M. A novel cell-penetrating peptide suppresses breast tumorigenesis by inhibiting beta-catenin/LEF-1 signaling. Sci. Rep. 2016, 6, 19156. [Google Scholar] [CrossRef]
- Bhattacharya, T.; Dutta, S.; Akter, R.; Rahman, H.; Karthika, C.; Nagaswarupa, H.P.; Murthy, H.C.A.; Fratila, O.; Brata, R.; Bungau, S. Role of Phytonutrients in Nutrigenetics and Nutrigenomics Perspective in Curing Breast Cancer. Biomolecules 2021, 11, 1176. [Google Scholar] [CrossRef]
- Han, H.S.; Koo, S.Y.; Choi, K.Y. Emerging nanoformulation strategies for phytocompounds and applications from drug delivery to phototherapy to imaging. Bioact. Mater. 2021, 14, 182–205. [Google Scholar] [CrossRef]
- Kotecha, R.; Takami, A.; Espinoza, J.L. Dietary phytochemicals and cancer chemoprevention: A review of the clinical evidence. Oncotarget 2016, 7, 52517–52529. [Google Scholar] [CrossRef]
- Shukla, Y.; Kalra, N. Cancer chemoprevention with garlic and its constituents. Cancer Lett. 2007, 247, 167–181. [Google Scholar] [CrossRef] [PubMed]
- Lei, X.Y.; Yao, S.Q.; Zu, X.Y.; Huang, Z.X.; Liu, L.J.; Zhong, M.; Zhu, B.Y.; Tang, S.S.; Liao, D.F. Apoptosis induced by diallyl disulfide in human breast cancer cell line MCF-7. Acta Pharmacol. Sin. 2008, 29, 1233–1239. [Google Scholar] [CrossRef] [PubMed]
- Sundaram, S.G.; Milner, J.A. Diallyl disulfide induces apoptosis of human colon tumor cells. Carcinogenesis 1996, 17, 669–763. [Google Scholar] [CrossRef] [PubMed]
- Sundaram, S.G.; Milner, J.A. Diallyl disulfide suppresses the growth of human colon tumor cell xenografts in athymic nude mice. J. Nutr. 1996, 126, 1355–1361. [Google Scholar] [CrossRef]
- Singh, S.V.; Mohan, R.R.; Agarwal, R.; Benson, P.J.; Hu, X.; Rudy, M.A.; Xia, H.; Katoh, A.; Srivastava, S.K.; Mukhtar, H.; et al. Novel anti-carcinogenic activity of an organosulfide from garlic: Inhibition of H-RAS oncogene transformed tumor growth in vivo by diallyl disulfide is associated with inhibition of p21H-ras processing. Biochem. Biophys. Res. Commun. 1996, 225, 660–665. [Google Scholar] [CrossRef]
- Knowles, L.M.; Milner, J.A. Possible mechanism by which allyl sulfides suppress neoplastic cell proliferation. J. Nutr. 2001, 131, 1061–1066. [Google Scholar] [CrossRef]
- Zhou, Y.F.; Zhu, Y.W.; Wang, Y.W.; Liang, X.Y.; Jiang, Q.Y.; Wu, D.D. Diallyl disulfide in oncotherapy: Molecular mechanisms and therapeutic potentials. Apoptosis 2025, 30, 1730–1750. [Google Scholar] [CrossRef]
- Brugnoli, F.; Tedeschi, P.; Grassilli, S.; Maietti, A.; Brandolini, V.; Bertagnolo, V. Ethanol-based garlic extract prevents malignant evolution of non-invasive breast tumor cells induced by moderate hypoxia. Biomed. Pharmacother. 2021, 142, 112052. [Google Scholar] [CrossRef]
- Petrovic, V.; Nepal, A.; Olaisen, C.; Bachke, S.; Hira, J.; Søgaard, C.K.; Røst, L.M.; Misund, K.; Andreassen, T.; Melø, T.M.; et al. Anti-Cancer Potential of Homemade Fresh Garlic Extract Is Related to Increased Endoplasmic Reticulum Stress. Nutrients 2018, 10, 450. [Google Scholar] [CrossRef] [PubMed]
- Brugnoli, F.; Dell’Aira, M.; Tedeschi, P.; Grassilli, S.; Pierantoni, M.; Foschi, R.; Bertagnolo, V. Effects of Garlic on Breast Tumor Cells with a Triple Negative Phenotype: Peculiar Subtype-Dependent Down-Modulation of Akt Signaling. Cells 2024, 13, 822. [Google Scholar] [CrossRef]
- Brugnoli, F.; Grassilli, S.; Al-Qassab, Y.; Capitani, S.; Bertagnolo, V. PLC-β2 is modulated by low oxygen availability in breast tumor cells and plays a phenotype dependent role in their hypoxia-related malignant potential. Mol. Carcinog. 2016, 55, 2210–2221. [Google Scholar] [CrossRef]
- Borcherding, N.; Bormann, N.L.; Voigt, A.P.; Zhang, W. TRGAted: A web tool for survival analysis using protein data in the cancer genome atlas. F1000Research 2018, 7, 1235. [Google Scholar] [CrossRef]
- Vranic, S.; Gatalica, Z.; Wang, Z.Y. Update on the molecular profile of the MDA-MB-453 cell line as a model for apocrine breast carcinoma studies. Oncol. Lett. 2011, 2, 1131–1137. [Google Scholar] [CrossRef]
- Zhang, M.Z.; Guan, Y.X.; Zhong, J.X.; Chen, X.Z. Preparation and Identification of HER2 Radioactive Ligands and Imaging Study of Breast Cancer-Bearing Nude Mice. Transl. Oncol. 2017, 10, 518–526. [Google Scholar] [CrossRef]
- Tedeschi, P.; Brugnoli, F.; Merighi, S.; Grassilli, S.; Nigro, M.; Catani, M.; Gessi, S.; Bertagnolo, V.; Travagli, A.; Caboni, M.F.; et al. The Effect of Different Storage Conditions on Phytochemical Composition, Shelf-Life, and Bioactive Compounds of Voghiera Garlic PDO. Antioxidants 2023, 12, 499. [Google Scholar] [CrossRef] [PubMed]
- Bartsch, R.; Pérez-García, J.M.; Furtner, J.; Berghoff, A.S.; Marhold, M.; Starzer, A.M.; Hughes, M.; Kabraji, S.; Sammons, S.; Anders, C.; et al. Results of a patient-level pooled analysis of three studies of trastuzumab deruxtecan in HER2-positive breast cancer with active brain metastasis. ESMO Open 2025, 10, 104092. [Google Scholar] [CrossRef] [PubMed]
- Lacruz, M.E.; Thies, S.; Schmidt-Pokrzywniak, A.; Wittenberg, I.; Engler, T.; Reinwald, F.; Klinkhammer-Schalke, M.; Zeissig, S.R.; Franke, B.; Weitmann, K.; et al. Clinical characteristics, metastasis patterns, and treatment outcomes of HER2-low breast cancer. Sci. Rep. 2025, 15, 4584. [Google Scholar] [CrossRef]
- Huang, J.; Yang, B.; Xiang, T.; Peng, W.; Qiu, Z.; Wan, J.; Zhang, L.; Li, H.; Li, H.; Ren, G. Diallyl disulfide inhibits growth and metastatic potential of human triple-negative breast cancer cells through inactivation of the β-catenin signaling pathway. Mol. Nutr. Food Res. 2015, 59, 1063–1075. [Google Scholar] [CrossRef] [PubMed]
- Xiong, T.; Liu, X.W.; Huang, X.L.; Xu, X.F.; Xie, W.Q.; Zhang, S.J.; Tu, J. Tristetraprolin: A novel target of diallyl disulfide that inhibits the progression of breast cancer. Oncol. Lett. 2018, 15, 7817–7827. [Google Scholar] [CrossRef]
- Ziperstein, M.J.; Guzman, A.; Kaufman, L.J. Breast Cancer Cell Line Aggregate Morphology Does Not Predict Invasive Capacity. PLoS ONE 2015, 10, e0139523. [Google Scholar] [CrossRef]
- Pollard, T.D.; Cooper, J.A. Actin, a central player in cell shape and movement. Science 2009, 326, 1208–1212. [Google Scholar] [CrossRef]
- Gardel, M.L.; Schneider, I.C.; Aratyn-Schaus, Y.; Waterman, C.M. Mechanical integration of actin and adhesion dynamics in cell migration. Annu. Rev. Cell Dev. Biol. 2010, 26, 315–333. [Google Scholar] [CrossRef] [PubMed]
- Gkretsi, V.; Stylianopoulos, T. Cell adhesion and matrix stiffness: Coordinating cancer cell invasion and metastasis. Front. Oncol. 2018, 8, 145. [Google Scholar] [CrossRef] [PubMed]
- Ridley, A.J. Life at the leading edge. Cell 2011, 145, 1012–1022. [Google Scholar] [CrossRef]
- Merkhofer, E.; Cogswell, P.; Baldwin, A. Her2 activates NF-κB and induces invasion through the canonical pathway involving IKKα. Oncogene 2010, 29, 1238–1248. [Google Scholar] [CrossRef]
- Ruiz-Saenz, A.; Dreyer, C.; Campbell, M.R.; Steri, V.; Gulizia, N.; Moasser, M.M. HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3. Cancer Res. 2018, 78, 3645–3658. [Google Scholar] [CrossRef]
- Deng, S.; Leong, H.C.; Datta, A.; Gopal, V.; Kumar, A.P.; Yap, C.T. PI3K/AKT Signaling Tips the Balance of Cytoskeletal Forces for Cancer Progression. Cancers 2022, 14, 1652. [Google Scholar] [CrossRef]
- Hinz, N.; Jücker, M. Distinct functions of AKT isoforms in breast cancer: A comprehensive review. Cell Commun. Signal. 2019, 17, 154. [Google Scholar] [CrossRef]
- Cerma, K.; Piacentini, F.; Moscetti, L.; Barbolini, M.; Canino, F.; Tornincasa, A.; Caggia, F.; Cerri, S.; Molinaro, A.; Dominici, M.; et al. Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges. Biomedicines 2023, 11, 109. [Google Scholar] [CrossRef]
- He, R.; Du, S.; Lei, T.; Xie, X.; Wang, Y. Glycogen Synthase Kinase 3β in Tumorigenesis and Oncotherapy. Oncol. Rep. 2020, 44, 2373–2385. [Google Scholar] [CrossRef]
- Cuello-Carrión, F.D.; Shortrede, J.E.; Alvarez-Olmedo, D.; Cayado-Gutiérrez, N.; Castro, G.N.; Zoppino, F.C.; Guerrero, M.; Martinis, E.; Wuilloud, R.; Gómez, N.N.; et al. HER2 and β-catenin protein location: Importance in the prognosis of breast cancer patients and their correlation when breast cancer cells suffer stressful situations. Clin. Exp. Metastasis 2015, 32, 151–168. [Google Scholar] [CrossRef]
- Li, J.; Zhou, B.P. Activation of β-catenin and Akt pathways by Twist are critical for the maintenance of EMT associated cancer stem cell-like characters. BMC Cancer 2011, 11, 49. [Google Scholar] [CrossRef]
- Li, S.; Li, S.; Sun, Y.; Li, L. The expression of β-catenin in different subtypes of breast cancer and its clinical significance. Tumour Biol. 2014, 35, 7693–7698. [Google Scholar] [CrossRef]
- Kanarek, N.; Petrova, B.; Sabatini, D.M. Dietary modifications for enhanced cancer therapy. Nature 2020, 579, 507–517. [Google Scholar] [CrossRef]
- Xiao, Y.L.; Gong, Y.; Qi, Y.J.; Shao, Z.M.; Jiang, Y.Z. Effects of dietary intervention on human diseases: Molecular mechanisms and therapeutic potential. Signal Transduct. Target. Ther. 2024, 9, 59. [Google Scholar] [CrossRef] [PubMed]
- Koundouros, N.; Nagiec, M.J.; Bullen, N.; Noch, E.K.; Burgos-Barragan, G.; Li, Z.; He, L.; Cho, S.; Parang, B.; Leone, D.; et al. Direct sensing of dietary ω-6 linoleic acid through FABP5-mTORC1 signaling. Science 2025, 387, eadm9805. [Google Scholar] [CrossRef] [PubMed]
- Talib, W.H.; Atawneh, S.; Shakhatreh, A.N.; Shakhatreh, G.N.; Rasheed aljarrah, I.S.; Hamed, R.A.; Adel Banyyounes, D.; Al-Yasari, I.H. Anticancer potential of garlic bioactive constituents: Allicin, Z-ajoene, and organosulfur compounds. PHARMACIA 2024, 71, 1–23. [Google Scholar] [CrossRef]
- Liu, Y.; Zhao, Y.; Wei, Z.; Tao, L.; Sheng, X.; Wang, S.; Chen, J.; Ruan, J.; Liu, Z.; Cao, Y.; et al. Targeting Thioredoxin System with an Organosulfur Compound, Diallyl Trisulfide (DATS), Attenuates Progression and Metastasis of Triple-Negative Breast Cancer (TNBC) Cell. Physiol. Biochem. 2018, 50, 1945–1963. [Google Scholar] [CrossRef]
- Peippo, M.; Gardberg, M.; Kronqvist, P.; Carpén, O.; Heuser, V.D. Characterization of Expression and Function of the Formins FHOD1, INF2, and DAAM1 in HER2-Positive Breast Cancer. J. Breast Cancer 2023, 26, 525–543. [Google Scholar] [CrossRef] [PubMed]
- El-Saadony, M.T.; Saad, A.M.; Korma, S.A.; Salem, H.M.; Abd El-Mageed, T.A.; Alkafaas, S.S.; Elsalahaty, M.I.; Elkafas, S.S.; Mosa, W.F.A.; Ahmed, A.E.; et al. Garlic bioactive substances and their therapeutic applications for improving human health: A comprehensive review. Front. Immunol. 2024, 15, 1277074. [Google Scholar] [CrossRef] [PubMed]
- Li, Y.; Wang, Z.; Li, J.; Sang, X. Diallyl disulfide suppresses FOXM1-mediated proliferation and invasion in osteosarcoma by upregulating miR-134. J. Cell. Biochem. 2019, 120, 7286–7296. [Google Scholar] [CrossRef]
- Machado, A.R.T.; Tuttis, K.; Santos, P.W.D.S.; Aissa, A.F.; Antunes, L.M.G. Diallyl Disulfide Induces Chemosensitization to Sorafenib, Autophagy, and Cell Cycle Arrest and Inhibits Invasion in Hepatocellular Carcinoma. Pharmaceutics 2022, 14, 2582. [Google Scholar] [CrossRef]
- Lai, K.C.; Hsu, S.C.; Kuo, C.L.; Yang, J.S.; Ma, C.Y.; Lu, H.F.; Tang, N.Y.; Hsia, T.C.; Ho, H.C.; Chung, J.G. Diallyl sulfide, diallyl disulfide, and diallyl trisulfide inhibit migration and invasion in human colon cancer colo 205 cells through the inhibition of matrix metalloproteinase-2, -7, and -9 expressions. Environ. Toxicol. 2013, 28, 479–488. [Google Scholar] [CrossRef]
- Su, J.; Zhou, Y.; Pan, Z.; Shi, L.; Yang, J.; Liao, A.; Liao, Q.; Su, Q. Downregulation of LIMK1-ADF/cofilin by DADS inhibits the migration and invasion of colon cancer. Sci. Rep. 2017, 7, 45624. [Google Scholar] [CrossRef]
- Hiremath, I.S.; Goel, A.; Warrier, S.; Kumar, A.P.; Sethi, G.; Garg, M. The multidimensional role of the Wnt/beta-catenin signaling pathway in human malignancies. J. Cell. Physiol. 2022, 237, 199–238. [Google Scholar] [CrossRef]
- Hashemi, M.; Hasani, S.; Hajimazdarany, S.; Ghadyani, F.; Olyaee, Y.; Khodadadi, M.; Ziyarani, M.F.; Dehghanpour, A.; Salehi, H.; Kakavand, A.; et al. Biological functions and molecular interactions of Wnt/β-catenin in breast cancer: Revisiting signaling networks. Int. J. Biol. Macromol. 2023, 232, 123377. [Google Scholar] [CrossRef] [PubMed]
- Gijsen, M.; King, P.; Perera, T.; Parker, P.J.; Harris, A.L.; Larijani, B.; Kong, A. HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer. PLoS Biol. 2016, 14, e1002414. [Google Scholar] [CrossRef] [PubMed]
- Mondal, A.; Banerjee, S.; Bose, S.; Mazumder, S.; Haber, R.A.; Farzaei, M.H.; Bishayee, A. Garlic constituents for cancer prevention and therapy: From phytochemistry to novel formulations. Pharmacol. Res. 2022, 175, 105837. [Google Scholar] [CrossRef] [PubMed]
- Lee, J.; Zhao, N.; Fu, Z.; Choi, J.; Lee, H.J.; Chung, M. Effects of garlic intake on cancer: A systematic review of randomized clinical trials and cohort studies. Nutr. Res. Pract. 2021, 15, 773–788. [Google Scholar] [CrossRef]










Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Dell’Aira, M.; Grassilli, S.; Pierantoni, M.; Bertagnolo, V.; Brugnoli, F. Dual Role of Diallyl Disulfide (DADS) on Invasive Potential and β-Catenin Dynamics in HER2-Positive Breast Cancer Cells. Cancers 2025, 17, 3572. https://doi.org/10.3390/cancers17213572
Dell’Aira M, Grassilli S, Pierantoni M, Bertagnolo V, Brugnoli F. Dual Role of Diallyl Disulfide (DADS) on Invasive Potential and β-Catenin Dynamics in HER2-Positive Breast Cancer Cells. Cancers. 2025; 17(21):3572. https://doi.org/10.3390/cancers17213572
Chicago/Turabian StyleDell’Aira, Marcello, Silvia Grassilli, Marina Pierantoni, Valeria Bertagnolo, and Federica Brugnoli. 2025. "Dual Role of Diallyl Disulfide (DADS) on Invasive Potential and β-Catenin Dynamics in HER2-Positive Breast Cancer Cells" Cancers 17, no. 21: 3572. https://doi.org/10.3390/cancers17213572
APA StyleDell’Aira, M., Grassilli, S., Pierantoni, M., Bertagnolo, V., & Brugnoli, F. (2025). Dual Role of Diallyl Disulfide (DADS) on Invasive Potential and β-Catenin Dynamics in HER2-Positive Breast Cancer Cells. Cancers, 17(21), 3572. https://doi.org/10.3390/cancers17213572

